Ovarian cancer trials in Belgium

In Belgium 45 Also abroad 795

45 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Where
Edegem, Gent, Leuven, Liège, Namur
Age
18 years and over
People
770 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06824467 · EU 2023-508015-23-00
Phase 3Taking people
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Where
Anderlecht, Charleroi, Gent, Leuven
Age
18 years and over
People
900 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07318558 · EU 2023-508047-40-00
Phase 3Taking people
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Where
Brussels, Edegem, Leuven
Age
18 years and over
People
420 worldwide
Run by
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT07546500
No phaseTaking people
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Where
Edegem
Age
18 years and over
People
730
Run by
Universiteit Antwerpen
See details and how to joinNCT07902375
Phase 3Taking people
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Where
Anderlecht, Bruges, Edegem, Ghent, Leuven
Age
18 years and over
People
1,630 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07213804 · EU 2025-522255-25-00
Phase 1/2Taking people
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Where
Gent, Kortrijk, Leuven, Mechelen, Sint-Lambrechts-Woluwe
Age
18 years and over
People
334 worldwide
Run by
Gilead Sciences
See details and how to joinNCT06303505 · EU 2024-511074-80-01
Phase 3Taking people
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Where
Edegem, Gent, Leuven, Liège, Namur
Age
18 years and over
People
270 worldwide
Run by
Verastem, Inc.
See details and how to joinNCT06072781 · EU 2023-508204-38-00
Phase 3Taking people
Phase 3 Study of Azenosertib Versus Chemotherapy in Platinum-Resistant Ovarian Cancers Positive for Cyclin E1 Protein Expression
Where
Brussels, Leuven
Age
18 years and over
People
197 worldwide
Run by
K-Group Beta Inc.
See details and how to join2025-524641-27-00 · EU 2025-524641-27-00
Phase 2Taking people
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Where
Leuven, Sint-Lambrechts-Woluwe
Age
18 years and over
People
310 worldwide
Run by
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT05128825 · EU 2022-502983-19-00
Phase 3Taking people
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Where
Gent, Leuven, Liège, Namur, Sint-Lambrechts-Woluwe
Age
18 years and over
People
582 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06819007 · EU 2024-516982-35-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Brussels, Edegem, Ghent, Jette, Leuven
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Charleroi, Gent, Leuven, Liège, Sint-Lambrechts-Woluwe
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 2Taking people
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
Where
Gent, Hasselt, Leuven, Sint-Lambrechts-Woluwe
Age
18 years and over
People
640 worldwide
Run by
North Eastern German Society of Gynaecological Oncology
See details and how to joinNCT05460000 · EU 2022-502559-69-01
No phaseNot yet taking people in Belgium
AI Analysis of CT Scans to Classify Ovarian Tumours as Benign, Borderline or Malignant Before Surgery
Where
Ghent
Age
18 years and over
People
1,300 worldwide
Run by
Catharina Ziekenhuis Eindhoven
See details and how to joinNCT07883551
Phase 3Taking people
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Where
Anderlecht, Gent, Kortrijk, Leuven, Sint-Lambrechts-Woluwe
Age
18 years and over
People
466 worldwide
Run by
Incyte Corporation
See details and how to joinNCT07214779 · EU 2025-522748-42-00
Phase 1/2Taking people
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Where
Anderlecht, Leuven
Age
18 years and over
People
460 worldwide
Run by
AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01
Phase 2Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Where
Gent, Leuven, Liège, Namur, Sint-Lambrechts-Woluwe
Age
18 years and over
People
400 worldwide
Run by
AbbVie
See details and how to joinNCT07059845 · EU 2025-521606-18-00
Phase 1Taking people
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Where
Kortrijk, Leuven, Liège
Age
15 years and over
People
282 worldwide
Run by
Xencor, Inc.
See details and how to joinNCT06276491
Phase 3Taking people
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
Where
Gent, Hasselt, Leuven, Libramont-Chevigny, Liège, Roeselare, Sint-Lambrechts-Woluwe, Sint-Niklaas
Age
18 years and over
People
544 worldwide
Run by
Genmab
See details and how to joinNCT07225270 · EU 2025-522167-15-00
Phase 1/2Taking people
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Where
Edegem, Gerpinnes, Leuven
Age
18 years and over
People
890 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT03564340 · EU 2024-510783-23-00
Phase 1/2Taking people
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Where
Leuven
Age
18 years and over
People
612 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT04590326 · EU 2022-501904-83-00
Phase 2Taking people
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Where
Anderlecht, Kortrijk, Leuven, Liège, Sint-Lambrechts-Woluwe
Age
18 years to 99 years
People
160 worldwide
Run by
Incyte Corporation
See details and how to joinNCT07023627 · EU 2025-521513-14-00
Phase 1/2Taking people
Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer
Where
Gent, Leuven, Liège, Sint-Lambrechts-Woluwe
Age
18 years and over
People
72 worldwide
Run by
Gilead Sciences
See details and how to joinNCT07736937 · EU 2025-524691-33-00
Phase 1Taking people
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
Where
Sint-Lambrechts-Woluwe
Age
18 years and over
People
187 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07306559 · EU 2025-522913-45-00
Phase 1/2Taking people
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Where
Antwerp, Brussels, Liège
Age
18 years and over
People
230 worldwide
Run by
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
See details and how to joinNCT05985655